Dr. Choi is the founder of ILIAS Biologics, Inc. and a pioneer in exosome-based protein drug delivery systems. As a professor at the Korea Advanced Institute of Science and Technology (KAIST), Dr. Choi has published over 130 papers in major scientific journals and obtained over 30 international patents. He established the exosome-based platform technology for protein drug delivery which became the foundation of ILIAS Biologics. He also developed the world’s first medical imaging device for diabetic peripheral vascular disease. Dr. Choi earned his M.D. in Medicine and Ph.D. in Microbiology from Yonsei University, College of Medicine.
Exosome Engineering for Active Targeting and Intracellular Delivery of Therapeutic Proteins: Realization from Concept
Wednesday, 14 December 2022 at 09:30
Add to Calendar ▼2022-12-14 09:30:002022-12-14 10:30:00Europe/LondonExosome Engineering for Active Targeting and Intracellular Delivery of Therapeutic Proteins: Realization from ConceptExtracellular Vesicles 2022: Technologies Driving Biological Investigations in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com
As extracellular vesicles that play an active role in intercellular communication by transferring cellular materials to recipient cells, exosome offer great potential as a natural therapeutic drug delivery vehicle. Currently, both academia and industry try to develop exosome platform-based therapeutics for disease management, some of which are already in clinical trials. An opto-genetically engineered exosome system (EXPLOR®) that we previously developed was implemented for loading therapeutic cargo into exosomes which can deliver therapeutic cargos into target cells in free form. We are studying the clinical potential of ‘Exo-target®’, therapeutic exosomes with EXPLOR technology, in multiple disease areas including inflammatory diseases. NF-kB has been well accepted as master regulator for inflammation. The introduction of I-kB into target cells can inhibit inflammatory responses by restraining nuclear translocation of NF-kB. Therefore, we have developed Exo-target loaded with dominant active form of I-kB (Exo-srI-kB). We found that Exo-srI-kB treatment attenuates both local and systemic inflammation and animal mortality associated inflammatory disease including sepsis, ischemic reperfusion induced acute kidney injury and preterm birth in our preclinical studies. Especially, maternally injected Exo-srI-kB could cross-over placenta barrier to deliver therapeutic cargos to fetal side, which resulted in prolonged pregnancy by more than 24 hours and additional advantages. Altogether, these results suggest therapeutic value of Exo-target for various disease by delivering API intracellularly to the target cells.
Add to Calendar ▼2022-12-12 00:00:002022-12-14 00:00:00Europe/LondonExtracellular Vesicles 2022: Technologies Driving Biological InvestigationsExtracellular Vesicles 2022: Technologies Driving Biological Investigations in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-12-14 09:30:002022-12-14 10:30:00Europe/LondonExosome Engineering for Active Targeting and Intracellular Delivery of Therapeutic Proteins: Realization from ConceptExtracellular Vesicles 2022: Technologies Driving Biological Investigations in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com
